Zydus Lifesciences entered into exclusive negotiations to purchase from PAI Partners and Amplitude Surgical’s management, as well as two minority shareholders, 85.6% of the share capital of Amplitude Surgical for €6.25 per Amplitude Surgical share.
Amplitude Surgical, based in France, is focused on the design and development of knee and hip prostheses. The company has experienced significant growth over the last four years, driven by new product development, international growth, investments in manufacturing capabilities and R&D. In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of €106.0 million. For the six months ended December 31, 2024, the company’s consolidated sales amounted to €51.5 million, growth of 5% year over year.
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said: “Our legacy in science, health and innovation has enabled a deep understanding of patient journey and their care pathways. We believe this was a natural extension in the field of medical technology. Our commitment to quality excellence, continuous investments in R&D and expertise in manufacturing will guide our foray into highly specialised MedTech products, adding a new dimension to our operations. In Amplitude Surgical, we see several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing and geographies.”
Olivier Jallabert, CEO and Founder, Amplitude Surgical, said: “The Amplitude Surgical team and I are delighted to join Zydus. This acquisition by a worldwide healthcare leader is a testament to the successful development of the Company over the last 25+ years, originally as a national orthopedics challenger and today as a European leader.”
Zydus Lifesciences entered into exclusive negotiations to purchase from PAI Partners and Amplitude Surgical’s management, as well as two minority shareholders, 85.6% of the share capital of Amplitude Surgical for €6.25 per Amplitude Surgical share.
Amplitude Surgical, based in France, is focused on the design and development of knee and hip...
Zydus Lifesciences entered into exclusive negotiations to purchase from PAI Partners and Amplitude Surgical’s management, as well as two minority shareholders, 85.6% of the share capital of Amplitude Surgical for €6.25 per Amplitude Surgical share.
Amplitude Surgical, based in France, is focused on the design and development of knee and hip prostheses. The company has experienced significant growth over the last four years, driven by new product development, international growth, investments in manufacturing capabilities and R&D. In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of €106.0 million. For the six months ended December 31, 2024, the company’s consolidated sales amounted to €51.5 million, growth of 5% year over year.
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said: “Our legacy in science, health and innovation has enabled a deep understanding of patient journey and their care pathways. We believe this was a natural extension in the field of medical technology. Our commitment to quality excellence, continuous investments in R&D and expertise in manufacturing will guide our foray into highly specialised MedTech products, adding a new dimension to our operations. In Amplitude Surgical, we see several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing and geographies.”
Olivier Jallabert, CEO and Founder, Amplitude Surgical, said: “The Amplitude Surgical team and I are delighted to join Zydus. This acquisition by a worldwide healthcare leader is a testament to the successful development of the Company over the last 25+ years, originally as a national orthopedics challenger and today as a European leader.”
Copy to clipboard 
